CO2021004681A2 - Use of reboxetine for the treatment of narcolepsy - Google Patents
Use of reboxetine for the treatment of narcolepsyInfo
- Publication number
- CO2021004681A2 CO2021004681A2 CONC2021/0004681A CO2021004681A CO2021004681A2 CO 2021004681 A2 CO2021004681 A2 CO 2021004681A2 CO 2021004681 A CO2021004681 A CO 2021004681A CO 2021004681 A2 CO2021004681 A2 CO 2021004681A2
- Authority
- CO
- Colombia
- Prior art keywords
- narcolepsy
- reboxetine
- treatment
- cataplexy
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Abstract
En la presente se describen métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.Described herein are methods for the treatment of cataplexy narcolepsy, comprising administering reboxetine to a human in need of it. Reboxetine can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions for using the pharmaceutical composition to treat cataplexy narcolepsy in a human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745956P | 2018-10-15 | 2018-10-15 | |
PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021004681A2 true CO2021004681A2 (en) | 2021-06-21 |
Family
ID=70284075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0004681A CO2021004681A2 (en) | 2018-10-15 | 2021-04-14 | Use of reboxetine for the treatment of narcolepsy |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3866768A4 (en) |
JP (1) | JP2022504975A (en) |
KR (1) | KR20210071046A (en) |
CN (1) | CN112888430A (en) |
AU (2) | AU2019361915A1 (en) |
BR (1) | BR112021007019A2 (en) |
CA (1) | CA3115983A1 (en) |
CL (1) | CL2021000924A1 (en) |
CO (1) | CO2021004681A2 (en) |
CR (1) | CR20210514A (en) |
EC (1) | ECSP21031200A (en) |
IL (1) | IL282311A (en) |
MX (1) | MX2021004207A (en) |
PE (1) | PE20211199A1 (en) |
SG (1) | SG11202103588WA (en) |
WO (1) | WO2020081461A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
KR20230055668A (en) * | 2021-10-19 | 2023-04-26 | 단국대학교 천안캠퍼스 산학협력단 | Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
AU2005256944A1 (en) * | 2004-06-09 | 2006-01-05 | Pfizer Inc. | Use of reboxetine for the treatment of pain |
KR102192554B1 (en) * | 2013-03-13 | 2020-12-18 | 에스케이바이오팜 주식회사 | Treatment of cataplexy |
-
2019
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en unknown
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/en active Pending
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/en not_active IP Right Cessation
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/en active Pending
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/en unknown
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/en unknown
- 2019-10-14 CR CR20210514A patent/CR20210514A/en unknown
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/en unknown
- 2019-10-14 CA CA3115983A patent/CA3115983A1/en active Pending
-
2021
- 2021-04-13 IL IL282311A patent/IL282311A/en unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/en unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/en unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/en unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20211199A1 (en) | 2021-07-01 |
CR20210514A (en) | 2021-11-12 |
CL2021000924A1 (en) | 2021-09-03 |
EP3866768A4 (en) | 2022-01-05 |
SG11202103588WA (en) | 2021-05-28 |
EP3866768A1 (en) | 2021-08-25 |
WO2020081461A1 (en) | 2020-04-23 |
AU2023200917A1 (en) | 2023-03-23 |
IL282311A (en) | 2021-05-31 |
AU2019361915A1 (en) | 2021-05-13 |
ECSP21031200A (en) | 2021-05-31 |
CA3115983A1 (en) | 2020-04-23 |
MX2021004207A (en) | 2021-08-11 |
JP2022504975A (en) | 2022-01-13 |
CN112888430A (en) | 2021-06-01 |
KR20210071046A (en) | 2021-06-15 |
BR112021007019A2 (en) | 2021-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021004681A2 (en) | Use of reboxetine for the treatment of narcolepsy | |
DOP2023000187A (en) | ANTIBODIES TARGETTING HIV GP120 AND METHODS OF USE | |
DOP2019000180A (en) | INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME | |
CL2017002996A1 (en) | Tetra-substituted alkene compounds and their use | |
CL2022001743A1 (en) | Gamma-Hydroxybutyrate (GHB) Dosage | |
CL2016002516A1 (en) | "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct | |
BR112016027773A2 (en) | cell penetrating peptide, polynucleotide, recombinant botulinum toxin penetrating cell protein, recombinant expression vector, bacterium, pharmaceutical composition, cosmetic composition and method for producing a recombinant botulinum toxin cell penetrating protein | |
GT201700246A (en) | METHODS AND KITS TO TREAT DEPRESSION | |
CL2008001268A1 (en) | Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain. | |
CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
CO2021015793A2 (en) | Methods of treating or preventing asthma by administering an il-33 antagonist | |
BR112017006113A8 (en) | Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits. | |
BR112023005160A2 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
CL2021001976A1 (en) | Treatment of skin lesions and pruritus in patients with nodular prurigo | |
MX2020004513A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
BR112019004540A2 (en) | method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin | |
CL2022001079A1 (en) | Methods and compositions for the treatment of rett syndrome | |
CL2021003442A1 (en) | Pharmaceutical composition comprising idelalisib and defactinib; and methods for treating cancer. | |
BR112019001082A2 (en) | levodopa and carbidopa intestinal gel and methods of use | |
AR122344A1 (en) | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS | |
UY39257A (en) | AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND ITS USE | |
CL2022001476A1 (en) | Use of reboxetine to treat disorders of the nervous system | |
PE20230181A1 (en) | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS | |
CL2019003288A1 (en) | A pharmaceutical combination for the treatment of cancer. | |
AR112535A1 (en) | METHODS FOR THE TREATMENT OF TNFa-RELATED DISEASES |